China
China Approves Jaypirca Across All Lines of Therapy for CLL/SLL
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
September 30, 2026 | News
Hengrui Pharma Inks $2.6B Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Therapy
HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total pot...
September 30, 2026 | News
iRegene Advances Off-the-Shelf Retinal Cell Therapy Into Clinical Trials in US and China
Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. iReg...
September 30, 2026 | News
Leo Cancer Care Advances Upright Radiation Therapy Experience for Children
Leo Cancer Care has announced plans to further invest in the treatment experience for children undergoing radiation therapy. Following the world's fi...
September 29, 2026 | News
Innovent Expands Global Phase III IBI363 Trial to Non-Squamous NSCLC
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization...
September 29, 2026 | News
XtalPi Files US FDA IND for AI-Designed Gut-Restricted Pan-TRK Inhibitor KQTD-126
This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's ...
September 28, 2026 | News
Nutshell Therapeutics Secures FDA IND Clearance for AI-Discovered NRF2 Degrader NTS231
Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announc...
September 28, 2026 | News
Sanyou Bio, NovoCodex Join Forces to Advance Next-Generation ADC Therapeutics
Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") and NovoCodex Biopharmaceuticals Co., Ltd. ("NovoCodex") jointly announced that the two companies have f...
September 25, 2026 | News
Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies
- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
September 24, 2026 | News
Tsingke Launches High-Throughput Validation Workflow for AI-Designed Proteins and Antibodies
Tsingke announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed pro...
September 24, 2026 | News
XtalPi-Backed Viva-Thera Advances AI-Designed HIV Candidate to Preclinical Stage in Seven Months
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Th...
September 24, 2026 | News
Bestzyme Completes World’s First Automated Smart Production Line for Sweet Proteins
Bestzyme, a synthetic biology company under GenScript Biotech, announced the completion of the world's first dedicated, automated smart production li...
September 23, 2026 | News
Novartis Inks Up to $900M Global Licensing Deal with BoomRay for Radioligand Therapy Asset
Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision onco...
September 23, 2026 | News
IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer
MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...
September 21, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
